Kurt Schalper, MD, PhD

• Adebowale Adeniran
• Alessandro Santin
• Anees Chagpar
• Anna Wurtz
• Anne Chiang
• Annette Komlo
• Ashita Talsania
• Barani Kumar Rajendran
• Benjamin Y. Lu
• Brinda Emu
• Christos Hatzis
• Curtis Jamison Perry
• Daniel P. Petrylak
• Daniel Zelterman
• David Rimm
• Edward Kaftan
• Frederick Wilson
• Geliang Gan
• Guoping Cai
• Harriet Kluger
• Heather Gerrish
• Hongyu Zhao
• Jeremy Kortmansky
• Jianlei Gu
• Jiawei Wang
• Katerina Politi
• Kimberly L. Johung
• Kishu Ranjan
• Lajos Pusztai
• Lesley Devine
• Malini Harigopal
• Mario Sznol
• Michael Cecchini
• Michael Hurwitz
• Navid Hafez
• Patricia LoRusso
• Pei Hui
• Peter Gershkovich
• Roy S. Herbst
• Ruth R Montgomery
• Sarah Goldberg
• Saral Mehra
• Scott Gettinger
• Stacey Stein
• Thazin Nwe Aung
• Veronica Chiang
• Yalai Bai
• Yong Kong
• Yuval Kluger
• Zenta Walther

Breast Neoplasms; Pathology

• 1434P Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapyArabyarmohammadi S, Corredor G, de Rodas Gregorio M, Schalper K, Madabhushi A. 1434P Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy. Annals Of Oncology 2023, 34: s816. DOI: 10.1016/j.annonc.2023.09.2465.
• Triangular Analysis of Geographical Interplay of Lymphocytes (TriAnGIL): Predicting Immunotherapy Response in Lung CancerArabyarmohammadi S, Corredor G, Zhou Y, López de Rodas M, Schalper K, Madabhushi A. Triangular Analysis of Geographical Interplay of Lymphocytes (TriAnGIL): Predicting Immunotherapy Response in Lung Cancer. 2023, 14225: 797-807. DOI: 10.1007/978-3-031-43987-2_77.
• Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapyMartinez-Morilla S, Moutafi M, Fernandez A, Jessel S, Divakar P, Wong P, Garcia-Milian R, Schalper K, Kluger H, Rimm D. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy. OncoImmunology 2023, 12: 2260618. PMID: 37781235, PMCID: PMC10540659, DOI: 10.1080/2162402x.2023.2260618.
• The β1-adrenergic receptor links sympathetic nerves to T cell exhaustionGlobig A, Zhao S, Roginsky J, Maltez V, Guiza J, Avina-Ochoa N, Heeg M, Araujo Hoffmann F, Chaudhary O, Wang J, Senturk G, Chen D, O’Connor C, Pfaff S, Germain R, Schalper K, Emu B, Kaech S. The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature 2023, 622: 383-392. PMID: 37731001, PMCID: PMC10871066, DOI: 10.1038/s41586-023-06568-6.
• International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant TherapyDacic S, Travis W, Redman M, Saqi A, Cooper W, Borczuk A, Chung J, Glass C, Lopez J, Roden A, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne M, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee J, Berezowska S, Chou T, Kerr K, Nicholson A, Poleri C, Schalper K, Tsao M, Carbone D, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn P, Kris M, Belani C, Kelly K, Wistuba I, Committee I. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal Of Thoracic Oncology 2023, 18: 1290-1302. PMID: 37702631, DOI: 10.1016/j.jtho.2023.07.017.
• Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trialMonjazeb A, Daly M, Luxardi G, Maverakis E, Merleev A, Marusina A, Borowsky A, Mirhadi A, Shiao S, Beckett L, Chen S, Eastham D, Li T, Vick L, McGee H, Lara F, Garcia L, Morris L, Canter R, Riess J, Schalper K, Murphy W, Kelly K. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nature Communications 2023, 14: 5332. PMID: 37658083, PMCID: PMC10474145, DOI: 10.1038/s41467-023-40813-w.
• Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapyBiswas S, Kang K, Ng K, Radivoyevitch T, Schalper K, Zhang H, Lindner D, Thomas A, MacPherson D, Gastman B, Schrump D, Wong K, Velcheti V, Saunthararajah Y. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy. Cell Reports 2023, 42: 113016. PMID: 37597186, PMCID: PMC10528072, DOI: 10.1016/j.celrep.2023.113016.
• BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-γ PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASESVilarino N, de Rodas M, Lu B, Goldberg S, Schalper K. BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-γ PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES. Neuro-Oncology Advances 2023, 5: iii4-iii4. PMCID: PMC10402438, DOI: 10.1093/noajnl/vdad070.012.
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerCecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
• NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsCecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications 2023, 3: 1113-1117. PMID: 37377610, PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.
• Developing a definition of immune exclusion in cancer: results of a modified Delphi workshopClifton G, Rothenberg M, Ascierto P, Begley G, Cecchini M, Eder J, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai S, Provenzano P, Puré E, Ribas A, Schalper K, Fridman W. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. Journal For ImmunoTherapy Of Cancer 2023, 11: e006773. PMID: 37290925, PMCID: PMC10254706, DOI: 10.1136/jitc-2023-006773.
• Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.Costantini A, Ranjan K, Ferrone S, Schalper K. Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer. Journal Of Clinical Oncology 2023, 41: 2623-2623. DOI: 10.1200/jco.2023.41.16_suppl.2623.
• Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancerBarrera C, Corredor G, Viswanathan V, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm D, Velcheti V, Schalper K, Romero E, Madabhushi A. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. Npj Precision Oncology 2023, 7: 52. PMID: 37264091, PMCID: PMC10235089, DOI: 10.1038/s41698-023-00403-x.
• Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.Gettinger S, Wilson F, Goldberg S, Chiang A, Henick B, Rowen E, Gerrish H, Duffield E, Davies M, Dest V, Komlo A, Pope J, Cheng W, Schalper K, Herbst R. Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition. Journal Of Clinical Oncology 2023, 41: 9121-9121. DOI: 10.1200/jco.2023.41.16_suppl.9121.
• Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.Chiang A, Asghari H, Ashley K, Gettinger S, Goldberg S, Herbst R, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Schultz E, Skrzypczak S, Kingsford C, Schalper K. Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer. Journal Of Clinical Oncology 2023, 41: 8597-8597. DOI: 10.1200/jco.2023.41.16_suppl.8597.
• Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerRavi A, Hellmann M, Arniella M, Holton M, Freeman S, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin A, Vokes N, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde P, Anagnostou V, Riess J, Gibbons D, Pennell N, Velcheti V, Digumarthy S, Mino-Kenudson M, Califano A, Heymach J, Herbst R, Brahmer J, Schalper K, Velculescu V, Henick B, Rizvi N, Jänne P, Awad M, Chow A, Greenbaum B, Luksza M, Shaw A, Wolchok J, Hacohen N, Getz G, Gainor J. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics 2023, 55: 807-819. PMID: 37024582, PMCID: PMC10181943, DOI: 10.1038/s41588-023-01355-5.
• Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulationSchalper K, Matsuda A, Ganno-Sherwood M, Maldonado-Lopez A, Rosentrater E, Porciuncula A, Zhang D, Christensen C, Merrigan S, Hatten T, Lee H, Lee M, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Harbison C, Parent A, Lineberry N, Abu-Yousif A, Appleman V. Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation. Cancer Research 2023, 83: 1841-1841. DOI: 10.1158/1538-7445.am2023-1841.
• Abstract 2508: Clinical significance of PARP7 ( TIPARP ) gene copy number alterations in human non-small cell and head & neck carcinomasAhumada V, McEachern K, Kuplast-Barr K, Schalper K. Abstract 2508: Clinical significance of PARP7 ( TIPARP ) gene copy number alterations in human non-small cell and head & neck carcinomas. Cancer Research 2023, 83: 2508-2508. DOI: 10.1158/1538-7445.am2023-2508.
• Abstract 6762: Tumor immune microenvironment &genomic features of non-small cell lung carcinomas in patients with HIV (PWH)Desai S, Ranjan K, Salahuddin S, Yusuf R, Gu J, Tang D, Kong Y, Rajendran B, Zhao H, Kluger Y, Goldberg S, Emu B, Schalper K. Abstract 6762: Tumor immune microenvironment &genomic features of non-small cell lung carcinomas in patients with HIV (PWH). Cancer Research 2023, 83: 6762-6762. DOI: 10.1158/1538-7445.am2023-6762.
• Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck CancerSalahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper K, Mehra S, Yarbrough W, Emu B. Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer. Clinical Infectious Diseases 2022, 76: 1449-1458. PMID: 36520995, PMCID: PMC10319962, DOI: 10.1093/cid/ciac924.
• 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592Gettinger S, Schenker M, De Langen J, Fischer J, Morgensztern D, Ciuleanu T, Beck T, De Castro Carpeno J, Schumann C, Yang X, Telivala B, Deschepper K, Nadal E, Schalper K, Spires T, Balli D, Nassar A, Karam S, Bhingare A, Spigel D. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. Immuno-Oncology Technology 2022, 16: 100107. DOI: 10.1016/j.iotech.2022.100107.
• P2.12-01 Intratumoral Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)Porciuncula A, Henick B, Gianino N, Zugazagoitia J, Vathiotis I, Gavrielatou N, Zacharek S, Rimm D, Schalper K. P2.12-01 Intratumoral Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC). Journal Of Thoracic Oncology 2022, 17: s150. DOI: 10.1016/j.jtho.2022.07.249.
• OA09.04 Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue ImagingDesai S, Sanmamed M, Wang J, Schalper K. OA09.04 Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue Imaging. Journal Of Thoracic Oncology 2022, 17: s25. DOI: 10.1016/j.jtho.2022.07.049.
• Abstract 2028: Spatially resolved proteomic profiling identifies tumor cell CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade in advanced non-small cell lung cancer (NSCLC)Moutafi M, Molero M, Martinez-Morilla S, Baena J, Vathiotis I, Gavrielatou N, Castro L, Ruiz de Garibay G, Adradas V, Orive D, Valencia K, Galvo A, Montuenga L, Ponce S, Schalper K, Paz-Ares L, Rimm D, Zugazagoitia J. Abstract 2028: Spatially resolved proteomic profiling identifies tumor cell CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade in advanced non-small cell lung cancer (NSCLC). Cancer Research 2022, 82: 2028-2028. DOI: 10.1158/1538-7445.am2022-2028.
• Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)Gregorio M, Nagineni V, Ravi A, Datar I, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm D, Herbst R, Madabhushi A, Riess J, Velcheti V, Hellmann M, Gainor J, Schalper K. Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC). Cancer Research 2022, 82: 1722-1722. DOI: 10.1158/1538-7445.am2022-1722.
• Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Stadler Z, Yaeger R, Smith J, Saltz L, El Dika I, Crane C, Romesser P, Iyer K, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser M, Schalper K, Diaz L. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. Journal Of Clinical Oncology 2022, 40: lba5-lba5. DOI: 10.1200/jco.2022.40.17_suppl.lba5.
• Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer.Salahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Schalper K, Mehra S, Yarbrough W, Emu B. Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer. Journal Of Clinical Oncology 2022, 40: e18080-e18080. DOI: 10.1200/jco.2022.40.16_suppl.e18080.
• Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.Corredor G, Ding R, Prasanna P, Barrera C, Toro P, Viswanathan V, Zens P, Berezowska S, Baxi V, Balli D, Belete M, Velcheti V, Schalper K, Madabhushi A. Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057. Journal Of Clinical Oncology 2022, 40: 2662-2662. DOI: 10.1200/jco.2022.40.16_suppl.2662.
• A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
• NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell CarcinomaJain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira A, Motoi N, Papotti M, Rekhtman N, Russell P, Prince S, Schmitt F, Yatabe Y, Eppenberger-Castori S, Bubendorf L, Beasley M, Berezowska S, Borczuk A, Brambilla E, Chou T, Chung J, Cooper W, Dacic S, Chan Y, Hirsch F, Hwang D, Joubert P, Kerr K, Lantuejoul S, Lin D, Lopez-Rios F, Matsubara D, Mino-Kenudson M, Nicholson A, Poleri C, Roden A, Schalper K, Sholl L, Thunnissen E, Travis W, Tsao M, Wistuba I, Chen G. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal Of Thoracic Oncology 2022, 17: 793-805. PMID: 35331963, DOI: 10.1016/j.jtho.2022.02.013.
• Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer.Zhang J, Cecchini M, Desai S, Schalper K. Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer. Journal Of Clinical Oncology 2022, 40: 136-136. DOI: 10.1200/jco.2022.40.4_suppl.136.
• 240 Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profilingMoutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung T, Yaghoobi V, Fernandez A, Fraile J, Schalper K, Rimm D. 240 Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling. Journal For ImmunoTherapy Of Cancer 2021, 9: a258-a258. DOI: 10.1136/jitc-2021-sitc2021.240.
• Tumor Microenvironment: Immune Effector and Suppressor ImbalanceSheehan K, Schalper K. Tumor Microenvironment: Immune Effector and Suppressor Imbalance. 2021, 1-25. DOI: 10.1007/978-3-030-74028-3_1.
• Abstract 418: Lower survival among HIV-infected head and neck cancer patientsSalahuddin S, Wu M, Irizarry J, Vega T, Isaeva N, Schalper K, Yarbrough W, Emu B. Abstract 418: Lower survival among HIV-infected head and neck cancer patients. 2021, 418-418. DOI: 10.1158/1538-7445.am2021-418.
• NTRK genomic alterations in Latin-American cancer patients.Carvajal D, Salas C, Marcelain K, Perez F, Rivas S, Feliu E, Schalper K, Arminsen R. NTRK genomic alterations in Latin-American cancer patients. Journal Of Clinical Oncology 2021, 39: e15088-e15088. DOI: 10.1200/jco.2021.39.15_suppl.e15088.
• P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung CancerRiess J, Schalper K, Kelly K, Shimoda M, Luxardi G, Merleev A, Monjazeb A, Danenberg K, Maverakis E, Gandara D. P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2021, 16: s345. DOI: 10.1016/j.jtho.2021.01.541.
• Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignanciesJimeno A, Gupta S, Sullivan R, Do K, Akerley W, Wang D, Teoh D, Schalper K, Zacharek S, Sun J, Laino A, Frederick J, Zhou H, Randolph W, Pascarella S, Johansen L, Cohen P, MEEHAN R, Bauer T. Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Cancer Research 2020, 80: ct032-ct032. DOI: 10.1158/1538-7445.am2020-ct032.
• Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancerDing A, Villarroel-Espindola F, Ducler A, Henick B, Desai S, Gianino N, Zugazagoitia J, Rimm D, Robert A, Cruzalegui F, Ferré P, Herbst R, Sanmamed M, Chen L, Schalper K. Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer. Cancer Research 2020, 80: 5525-5525. DOI: 10.1158/1538-7445.am2020-5525.
• Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLCLiu Y, Zugazagoitia J, Schalper K, Herbst R, Rimm D. Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC. Cancer Research 2020, 80: 2002-2002. DOI: 10.1158/1538-7445.am2020-2002.
• Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.LoRusso P, Pilat M, Santa-Maria C, Connolly R, Roesch E, Afghahi A, Han H, Nanda R, Wulf G, Assad H, Park H, Dees E, Force J, Noonan A, Brufsky A, Abramson V, Haley B, Buys S, Sharon E, Schalper K. Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer. Journal Of Clinical Oncology 2020, 38: tps1102-tps1102. DOI: 10.1200/jco.2020.38.15_suppl.tps1102.
• Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer.Kelly K, Daly M, Mirhadi A, Lara F, Garcia L, Chen S, Eastham D, Wiegner E, Riess J, Schalper K, Monjazeb A. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer. Journal Of Clinical Oncology 2020, 38: 9011-9011. DOI: 10.1200/jco.2020.38.15_suppl.9011.
• Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scoresDing R, Prasanna P, Corredor G, Lu C, Velu P, Le K, Leo P, Beig N, Velcheti V, Rimm D, Schalper K, Madabhushi A. Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores. 2020, 2. DOI: 10.1117/12.2549588.
• IA11 Role of the Tumor Microenvironment in Sensitivity and Resistance to Immunostimulatory Therapies in NSCLCSchalper K. IA11 Role of the Tumor Microenvironment in Sensitivity and Resistance to Immunostimulatory Therapies in NSCLC. Journal Of Thoracic Oncology 2020, 15: s4. DOI: 10.1016/j.jtho.2019.12.012.
• P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass CytometryYusuf R, Villarroel-Espindola F, Schalper K, Emu B. P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry. Journal Of Thoracic Oncology 2019, 14: s448. DOI: 10.1016/j.jtho.2019.08.926.
• MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung CancerWang X, Barrera C, Bera K, Lu C, Feldman M, Schalper K, Rimm D, Velcheti V, Madabhushi A. MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s350-s351. DOI: 10.1016/j.jtho.2019.08.710.
• MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLCVelcheti V, Lu C, Bera K, Wang X, Fu P, Yang M, Rimm D, Schalper K, Madabhushi A. MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC. Journal Of Thoracic Oncology 2019, 14: s310. DOI: 10.1016/j.jtho.2019.08.622.
• MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLCSkoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings A, Elamin Y, Lam V, Zhang J, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston R, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Lacroix L, Memmott R, Madrigal J, Goldman J, Lau S, Killam J, Walther Z, Carter B, Woodcock M, Roth J, Swisher S, Leighl N, Digumarthy S, Mooradian M, Rotow J, Wolf J, Scagliotti G, Planchard D, Besse B, Bivona T, Gandara D, Garon E, Rizvi N, Camidge D, Schalper K, Herbst R, Shaw A, Neal J, Wakelee H, Brahmer J, Jänne P, Carbone D, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach J. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal Of Thoracic Oncology 2019, 14: s294-s295. DOI: 10.1016/j.jtho.2019.08.591.
• Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patientsLiu Y, Zugazagoitia J, Henick B, Schalper K, Rimm D. Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients. Cancer Research 2019, 79: 2674-2674. DOI: 10.1158/1538-7445.am2019-2674.
• Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patientsLiu Y, Zugazagoitia J, Henick B, Schalper K, Rimm D. Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients. 2019, 2674-2674. DOI: 10.1158/1538-7445.sabcs18-2674.
• Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.Lu B, Gupta R, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. Journal Of Clinical Oncology 2019, 37: 2066-2066. DOI: 10.1200/jco.2019.37.15_suppl.2066.
• Phenotyping tumor infiltrating lymphocytes (PhenoTIL) on H&E tissue images: predicting recurrence in lung cancerBarrera C, Corredor G, Wang X, Schalper K, Rimm D, Velcheti V, Madabhushi A, Castro E. Phenotyping tumor infiltrating lymphocytes (PhenoTIL) on H&E tissue images: predicting recurrence in lung cancer. Progress In Biomedical Optics And Imaging 2019, 10956: 1095607-1095607-8. DOI: 10.1117/12.2513048.
• CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLCChristoph D, Gettinger S, Beck J, Yang X, Telivala B, Morgensztern D, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel. CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Pneumologie 2019, 73 DOI: 10.1055/s-0039-1678250.
• Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or MelanomaCampbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
• P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKIRiess J, Kelly K, Schalper K, Shimoda M, Lim S, Monjazeb A, Danenberg K, Moore E, Beckett L, Mack P, Maverakis E, Gandara D. P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI. Journal Of Thoracic Oncology 2018, 13: s528. DOI: 10.1016/j.jtho.2018.08.724.
• 1503TiP CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLCGettinger S, Beck T, Yang X, Telivala B, Morgensztern D, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel D. 1503TiP CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Annals Of Oncology 2018, 29: viii544-viii545. DOI: 10.1093/annonc/mdy292.124.
• Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer. Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
• Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumorsMorgado M, Datar I, Wang J, Sanmamed M, McEachern K, Jenkins D, Chen L, Carvajal-Hausdorf D, Rimm D, Herbst R, Schalper K. Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors. Cancer Research 2018, 78: 1681-1681. DOI: 10.1158/1538-7445.am2018-1681.
• PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Vaupel C, Schalper K, Rimm D, Velcheti V. PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC). Journal Of Clinical Oncology 2018, 36: 12059-12059. DOI: 10.1200/jco.2018.36.15_suppl.12059.
• Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?Khunger M, Bordeaux J, Dakappagari N, Vaupel C, Khunger A, Hu B, Schalper K, Rimm D, Velcheti V. Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter? Journal Of Clinical Oncology 2018, 36: 12058-12058. DOI: 10.1200/jco.2018.36.15_suppl.12058.
• PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases.Lu B, Gupta R, Ribeiro M, Stewart T, Chiang V, Contessa J, Adeniran A, Kluger H, Jilaveanu L, Schalper K, Goldberg S. PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases. Journal Of Clinical Oncology 2018, 36: e24116-e24116. DOI: 10.1200/jco.2018.36.15_suppl.e24116.
• Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).Datar I, Villarroel-Espindola F, Henick B, Syrigos K, Toki M, Rimm D, Ferrone S, Herbst R, Schalper K. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 12015-12015. DOI: 10.1200/jco.2018.36.15_suppl.12015.
• Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).Henick B, Datar I, Villarroel-Espindola F, Sanmamed M, Yu J, Tuktamyshov R, Li A, Toki M, Syrigos K, Rimm D, Chen L, Herbst R, Schalper K. Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). Journal Of Clinical Oncology 2018, 36: 12002-12002. DOI: 10.1200/jco.2018.36.15_suppl.12002.
• Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
• Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung CancerVillarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer. Clinical Cancer Research 2018, 24: 1562-1573. PMID: 29203588, PMCID: PMC5884702, DOI: 10.1158/1078-0432.ccr-17-2542.
• Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung CancerGettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.
• Abstract P2-09-18: Multiplexed (18-Plex) measurement of protein targets in trastuzumab-treated patients using imaging mass cytometryCarvajal-Hausdorf D, Stanton K, Patsenker J, Villarroel-Espindola F, Esch A, Montgomery R, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Schalper K, Kluger Y, Rimm D. Abstract P2-09-18: Multiplexed (18-Plex) measurement of protein targets in trastuzumab-treated patients using imaging mass cytometry. Cancer Research 2018, 78: p2-09-18-p2-09-18. DOI: 10.1158/1538-7445.sabcs17-p2-09-18.
• Safety and feasibility of immuno-cryotherapy.Raja J, Ghodadra A, Gettinger S, Kluger H, Sznol M, Schalper K, "Kevin" Kim H. Safety and feasibility of immuno-cryotherapy. Journal Of Clinical Oncology 2018, 36: 34-34. DOI: 10.1200/jco.2018.36.5_suppl.34.
• Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingRizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal Of Clinical Oncology 2018, 36: jco.2017.75.338. PMID: 29337640, PMCID: PMC6075848, DOI: 10.1200/jco.2017.75.3384.
• Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerGettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery 2017, 7: cd-17-0593. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.cd-17-0593.
• 15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockersDatar I, Sanmamed M, Choi J, Wang J, Henick B, Badri T, Mejias L, Lozano M, Gracia J, Velcheti V, Herbst R, Melero I, Chen L, Schalper K. 15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers. Annals Of Oncology 2017, 28: xi5. DOI: 10.1093/annonc/mdx710.006.
• MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung CancerSchneider J, Jain P, Schalper K, Lovly C, Gardner F, Ross J, Schrock A, Ali S, Miller V, Velcheti V. MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s1863. DOI: 10.1016/j.jtho.2017.09.588.
• PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung CancerWang X, Corredor G, Romero E, Schalper K, Yang M, Rimm D, Velcheti V, Madabhushi A. PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s2372-s2373. DOI: 10.1016/j.jtho.2017.09.1887.
• MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung CancerVelcheti V, Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Kim J, Schalper K, Rimm D. MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s1852. DOI: 10.1016/j.jtho.2017.09.562.
• Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E imagesWang X, Janowczyk A, Zhou Y, Thawani R, Fu P, Schalper K, Velcheti V, Madabhushi A. Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images. Scientific Reports 2017, 7: 13543. PMID: 29051570, PMCID: PMC5648794, DOI: 10.1038/s41598-017-13773-7.
• Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancerCarvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 81. PMID: 29037255, PMCID: PMC5644103, DOI: 10.1186/s40425-017-0285-7.
• Interleukin-8 in cancer pathogenesis, treatment and follow-upAlfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews 2017, 60: 24-31. PMID: 28866366, DOI: 10.1016/j.ctrv.2017.08.004.
• B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating LymphocytesAltan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research 2017, 23: 5202-5209. PMID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.ccr-16-3107.
• Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)Villarroel-Espindola F, Datar I, Velcheti V, Rimm D, Herbst R, Schalper K. Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC). Cancer Research 2017, 77: 5657-5657. DOI: 10.1158/1538-7445.am2017-5657.
• Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC)Datar I, Wang J, Mani N, Villarroel-Espindola F, Ryan P, Sanmamed M, McEachern K, Jenkins D, Rimm D, Chen L, Herbst R, Schalper K. Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC). Cancer Research 2017, 77: 5600-5600. DOI: 10.1158/1538-7445.am2017-5600.
• Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometryVillarroel-Espindola F, Carvajal-Hausdorf D, Datar I, Esch A, Rashidi N, Nassar A, Ren S, Montgomery R, Herbst R, Rimm D, Schalper K. Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry. Cancer Research 2017, 77: 1635-1635. DOI: 10.1158/1538-7445.am2017-1635.
• Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo.Kang K, Schrump D, Thomas A, Schalper K, Saunthararajah Y, Velcheti V. Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo. Journal Of Clinical Oncology 2017, 35: 11552-11552. DOI: 10.1200/jco.2017.35.15_suppl.11552.
• Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.
• Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significanceCarvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.
• Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerSchalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.ccr-16-0150.
• MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA TrialMorgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial. Journal Of Thoracic Oncology 2017, 12: s394-s395. DOI: 10.1016/j.jtho.2016.11.447.
• P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted TherapyAltan M, Pelekanou V, Schalper K, Toki M, Herbst R, Rimm D. P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy. Journal Of Thoracic Oncology 2017, 12: s813-s814. DOI: 10.1016/j.jtho.2016.11.1098.
• P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
• P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers. Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
• MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC). Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
• Strategies to design clinical studies to identify predictive biomarkers in cancer researchPerez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews 2016, 53: 79-97. PMID: 28088073, DOI: 10.1016/j.ctrv.2016.12.005.
• Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancerRehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Modern Pathology 2016, 30: 340-349. PMID: 27834350, PMCID: PMC5334264, DOI: 10.1038/modpathol.2016.186.
• Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and CrossprimingRodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research 2016, 76: 5994-6005. PMID: 27550452, DOI: 10.1158/0008-5472.can-16-0549.
• Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancerMani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research 2016, 18: 78. PMID: 27473061, PMCID: PMC4966732, DOI: 10.1186/s13058-016-0737-x.
• EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung AdenocarcinomaToki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2016, 11: 1901-1911. PMID: 27449805, PMCID: PMC5075503, DOI: 10.1016/j.jtho.2016.06.025.
• Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?Datar I, Schalper KA. Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg? Clinical Cancer Research 2016, 22: 3422-3424. PMID: 27076625, PMCID: PMC4947415, DOI: 10.1158/1078-0432.ccr-16-0336.
• Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurementZarrella ER, Coulter M, Welsh AW, Carvajal DE, Schalper KA, Harigopal M, Rimm D, Neumeister V. Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Laboratory Investigation 2016, 96: 1016-1025. PMID: 27348626, PMCID: PMC5008858, DOI: 10.1038/labinvest.2016.73.
• Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. Journal Of Clinical Oncology 2016, 34: tps9102-tps9102. DOI: 10.1200/jco.2016.34.15_suppl.tps9102.
• Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.Kang K, Rakshit S, Schalper K, Pennell N, Schrump D, Saunthararajah Y, Velcheti V. Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer. Journal Of Clinical Oncology 2016, 34: e14073-e14073. DOI: 10.1200/jco.2016.34.15_suppl.e14073.
• Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.Khunger M, Rakshit S, Schalper K, Elson P, Pennell N, Stevenson J, Velcheti V. Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors. Journal Of Clinical Oncology 2016, 34: 11603-11603. DOI: 10.1200/jco.2016.34.15_suppl.11603.
• Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.Gaule P, Rehman J, Smithy J, Toki M, Han G, Neumeister V, Carvajal-Hausdorf D, Schalper K, Pelekanou V, Wasserman B, Herbst R, Rimm D. Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. Journal Of Clinical Oncology 2016, 34: 9040-9040. DOI: 10.1200/jco.2016.34.15_suppl.9040.
• Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).Schalper K, Mani N, Toki M, Carvajal-Hausdorf D, Herbst R, Rimm D. Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 11610-11610. DOI: 10.1200/jco.2016.34.15_suppl.11610.
• Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
• Basic Overview of Current Immunotherapy Approaches in CancerVelcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society Of Clinical Oncology Educational Book 2016, 35: 298-308. PMID: 27249709, DOI: 10.1200/edbk_156572.
• Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for ResearchSchalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.
• Abstract P3-07-06: Objective measurement of HER2 (ERBB2) intracellular and extracellular domain spatial co-localization stratifies benefit from adjuvant trastuzumabCarvajal-Hausdorf D, Toki M, Schalper K, Pusztai L, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Rimm D. Abstract P3-07-06: Objective measurement of HER2 (ERBB2) intracellular and extracellular domain spatial co-localization stratifies benefit from adjuvant trastuzumab. Cancer Research 2016, 76: p3-07-06-p3-07-06. DOI: 10.1158/1538-7445.sabcs15-p3-07-06.
• Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarkerMani N, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker. Cancer Research 2016, 76: p5-07-09-p5-07-09. DOI: 10.1158/1538-7445.sabcs15-p5-07-09.
• Predictive biomarkers for immunotherapy in lung cancer: Opportunities and challengesSchalper K. Predictive biomarkers for immunotherapy in lung cancer: Opportunities and challenges. Journal Of Thoracic Oncology 2016, 11: s12-s13. DOI: 10.1016/j.jtho.2015.12.020.
• Basic Overview of Current Immunotherapy Approaches in CancerVelcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society Of Clinical Oncology Educational Book 2016, 36: 298-308. DOI: 10.14694/edbk_156572.
• Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerMcLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology 2016, 2: 1-9. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.
• Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancerVelcheti V, Pennell N, Rakshit S, Stevenson J, Shapiro M, Almeida F, Gurajala R, Schalper K, Saunthararajah Y. Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p178. PMCID: PMC4645121, DOI: 10.1186/2051-1426-3-s2-p178.
• Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancerSchalper K, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Chen L, Sanmamed M, Herbst R, Rimm D. Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p415. PMCID: PMC4652522, DOI: 10.1186/2051-1426-3-s2-p415.
• Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19Barrera F, Azocar L, Molina H, Schalper KA, Ocares M, Liberona J, Villarroel L, Pimentel F, Pérez-Ayuso RM, Nervi F, Groen AK, Miquel JF. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Annals Of Hepatology 2015, 14: 710-721. PMID: 26256900, DOI: 10.1016/s1665-2681(19)30766-5.
• Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient MiceSanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice. Cancer Research 2015, 75: 3466-3478. PMID: 26113085, DOI: 10.1158/0008-5472.can-14-3510.
• Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient miceSanmamed M, Rodriguez I, Oñate C, Azpilikueta A, Rodriguez-Ruiz M, Morales-Kastresana A, Labiano S, Perez-Gracia J, Martín-Algarra S, Alfaro C, Schalper K, Mazzolini G, Sarno F, Hidalgo M, Korman A, Jure-Kunkel M, Melero I. Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice. 2015, 261-261. DOI: 10.1158/1538-7445.am2015-261.
• Abstract 2347: Multiplexed quantitative assessment and prognostic value of TIL subtypes in non-small cell lung cancerSchalper K, Hoyt C, Wang C, Rimm D. Abstract 2347: Multiplexed quantitative assessment and prognostic value of TIL subtypes in non-small cell lung cancer. 2015, 2347-2347. DOI: 10.1158/1538-7445.am2015-2347.
• Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)McLaughlin J, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Velcheti V, Haack H, Silver M, Herbst R, LoRusso P, Rimm D. Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC). 2015, 1310-1310. DOI: 10.1158/1538-7445.am2015-1310.
• Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive ratsCarreño JE, Verdugo FJ, Contreras F, Montellano FA, Veloso S, Schalper KA, Sandoval M, Villanueva S, Marusic E, Irarrazabal CE. Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive rats. Journal Of The Renin-Angiotensin-Aldosterone System 2015, 16: 1225-1231. PMID: 25997821, DOI: 10.1177/1470320315587193.
• Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.Altan M, Schalper K, Silver M, Rimm D. Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer. Journal Of Clinical Oncology 2015, 33: 1087-1087. DOI: 10.1200/jco.2015.33.15_suppl.1087.
• Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Syrigos K, Herbst R, Rimm D. Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. Journal Of Clinical Oncology 2015, 33: 3067-3067. DOI: 10.1200/jco.2015.33.15_suppl.3067.
• The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.Hurwitz M, Adeniran A, Yao X, Hafez N, Schalper K, Rimm D, Petrylak D. The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers. Journal Of Clinical Oncology 2015, 33: e15504-e15504. DOI: 10.1200/jco.2015.33.15_suppl.e15504.
• Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast CancerCarvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25991002, PMCID: PMC4554192, DOI: 10.1093/jnci/djv136.
• Abstract P3-06-26: Measurement of domain-specific HER2 (ERBB2) expression classifies benefit from Trastuzumab in breast cancerCarvajal-Hausdorf D, Schalper K, Pusztai L, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Rimm D. Abstract P3-06-26: Measurement of domain-specific HER2 (ERBB2) expression classifies benefit from Trastuzumab in breast cancer. 2015, p3-06-26-p3-06-26. DOI: 10.1158/1538-7445.sabcs14-p3-06-26.
• PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast CancerWimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research 2015, 3: 326-332. PMID: 25527356, PMCID: PMC4390454, DOI: 10.1158/2326-6066.cir-14-0133.
• Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung CancerSchalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25650315, PMCID: PMC4565530, DOI: 10.1093/jnci/dju435.
• Quantitative measurement of cancer tissue biomarkers in the lab and in the clinicCarvajal-Hausdorf D, Schalper KA, Neumeister V, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Laboratory Investigation 2014, 95: 385-396. PMID: 25502176, PMCID: PMC4383674, DOI: 10.1038/labinvest.2014.157.
• Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insightsVelcheti V, Schalper K, Venur V. Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal Of Receptor Ligand And Channel Research 2014, Volume 8: 1-7. DOI: 10.2147/jrlcr.s39986.
• Quantitative Measurement of BIM Protein in Lung Cancer Diagnosis/StagingHenick B, Zarrella E, Altan M, McLaughlin J, Schalper K, Velcheti V, Rimm D. Quantitative Measurement of BIM Protein in Lung Cancer Diagnosis/Staging. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s11. DOI: 10.1016/j.ijrobp.2014.08.148.
• Unvalidated antibodies and misleading resultsRimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Research And Treatment 2014, 147: 457-458. PMID: 25086631, PMCID: PMC4216678, DOI: 10.1007/s10549-014-3061-0.
• Possible role of hemichannels in cancerSchalper KA, Carvajal-Hausdorf D, Oyarzo MP. Possible role of hemichannels in cancer. Frontiers In Physiology 2014, 5: 237. PMID: 25018732, PMCID: PMC4073485, DOI: 10.3389/fphys.2014.00237.
• PD-L1 expression and tumor-infiltrating lymphocytesSchalper KA. PD-L1 expression and tumor-infiltrating lymphocytes. OncoImmunology 2014, 3: e29288. PMID: 25083339, PMCID: PMC4106164, DOI: 10.4161/onci.29288.
• Clinical significance of TILs subtypes in non-small cell lung cancer.Schalper K, Brown J, McLaughlin J, Herbst R, Rimm D. Clinical significance of TILs subtypes in non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: 8082-8082. DOI: 10.1200/jco.2014.32.15_suppl.8082.
• Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).McLaughlin J, Schalper K, Carvajal-Hausdorf D, Velcheti V, Haack H, Silver M, Goldberg S, Herbst R, Rimm D. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8064-8064. DOI: 10.1200/jco.2014.32.15_suppl.8064.
• In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasSchalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clinical Cancer Research 2014, 20: 2773-2782. PMID: 24647569, DOI: 10.1158/1078-0432.ccr-13-2702.
• Automated Objective Determination of Percentage of Malignant Nuclei for Mutation TestingViray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing. Applied Immunohistochemistry & Molecular Morphology 2014, 22: 363-371. PMID: 24162261, PMCID: PMC3999345, DOI: 10.1097/pai.0b013e318299a1f6.
• Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointestinal Cancer Research : GCR 2014, 7: 42-8. PMID: 24799970, PMCID: PMC4007675.
• Mutacin del gen BRAF en pacientes con cnceres de colon y recto con KRAS no mutadoRoa I, Game A, Bizama C, Schalper K. Mutacin del gen BRAF en pacientes con cnceres de colon y recto con KRAS no mutado. Revista Medica De Chile 2014, 142: 55-60. PMID: 24861115, DOI: 10.4067/s0034-98872014000100009.
• Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancerWimberly H, Schalper K, Chen L, Velcheti V, Pusztai L, Rimm D. Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancer. Cancer Research 2013, 73: p2-10-02-p2-10-02. DOI: 10.1158/0008-5472.sabcs13-p2-10-02.
• Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trialRimm D, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial. Cancer Research 2013, 73: p1-08-09-p1-08-09. DOI: 10.1158/0008-5472.sabcs13-p1-08-09.
• Es posible utilizar las muestras de colecistectomas con cncer en investigacin?: Calidad del ADN de muestras obtenidas del sistema pblico y privado de saludRoa I, de Toro G, Snchez T, Slater J, Ziegler AM, Game A, Arellano L, Schalper K, de Aretxabala X. Es posible utilizar las muestras de colecistectomas con cncer en investigacin?: Calidad del ADN de muestras obtenidas del sistema pblico y privado de salud. Revista Medica De Chile 2013, 141: 1528-1533. PMID: 24728429, DOI: 10.4067/s0034-98872013001200005.
• Programmed death ligand-1 expression in non-small cell lung cancerVelcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation 2013, 94: 107-116. PMID: 24217091, PMCID: PMC6125250, DOI: 10.1038/labinvest.2013.130.
• Expresin y amplificacin del gen HER2 en el cncer gstrico avanzadoRoa I, Slater J, Carvajal D, Schalper K, de Toro G, Ares R, Game A, Len J, de Aretxabala X. Expresin y amplificacin del gen HER2 en el cncer gstrico avanzado. Revista Medica De Chile 2013, 141: 1411-1419. PMID: 24718467, DOI: 10.4067/s0034-98872013001100007.
• A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists CriteriaSchalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.
• Role of Gap Junctions and Hemichannels in Parasitic InfectionsVega JL, Subiabre M, Figueroa F, Schalper KA, Osorio L, González J, Sáez JC. Role of Gap Junctions and Hemichannels in Parasitic Infections. BioMed Research International 2013, 2013: 589130. PMID: 24236292, PMCID: PMC3819887, DOI: 10.1155/2013/589130.
• Mutacin del gen KRAS en el cncer de colon y rectoRoa I, Snchez T, Majlis A, Schalper K. Mutacin del gen KRAS en el cncer de colon y recto. Revista Medica De Chile 2013, 141: 1166-1172. PMID: 24522420, DOI: 10.4067/s0034-98872013000900009.
• Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous MelanomasViray H, Bradley WR, Schalper KA, Rimm DL, Rothberg B. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.
• Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)Velcheti V, Rimm DL, Schalper KA. Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal Of Thoracic Oncology 2013, 8: 803-805. PMID: 23676558, PMCID: PMC3703468, DOI: 10.1097/jto.0b013e318292be18.
• Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.
• High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung CarcinomasVelcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, Deng Y, Gettinger S, Rimm DL. High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas. PLOS ONE 2013, 8: e61427. PMID: 23620753, PMCID: PMC3631238, DOI: 10.1371/journal.pone.0061427.
• Abstract 1569: Next generation cell line models: conditionally reprogrammed cells.Agarwal S, Hu J, Stanton K, Schalper K, Kluger Y, Zarrella E, Liu X, Schlegel R, Rimm D. Abstract 1569: Next generation cell line models: conditionally reprogrammed cells. Cancer Research 2013, 73: 1569-1569. DOI: 10.1158/1538-7445.am2013-1569.
• Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradationRajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene 2013, 33: 1438-1447. PMID: 23542176, PMCID: PMC3815749, DOI: 10.1038/onc.2013.78.
• Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca).Javle M, Rashid A, Kar S, Schalper K, Wang N, Peto M, Vauthey J, Aloia T, De Aretxabala X, Mills G, Spellman P, Roa I. Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca). Journal Of Clinical Oncology 2013, 31: 214-214. DOI: 10.1200/jco.2013.31.4_suppl.214.
• Abstract P3-06-25: PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients.Schalper K, Li K, Rimm D. Abstract P3-06-25: PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients. Cancer Research 2012, 72: p3-06-25-p3-06-25. DOI: 10.1158/0008-5472.sabcs12-p3-06-25.
• In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.Vassilakopoulou M, Bordeaux J, Neumeister V, Cheng H, Schalper K, Skarlos D, Pectasides D, Pavlidis N, Koutras A, Linardou H, Razis E, Bobos M, Kotoula V, Rimm D, Fountzilas G, Psyrri A. In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients. Journal Of Clinical Oncology 2012, 30: 573-573. DOI: 10.1200/jco.2012.30.15_suppl.573.
• Regulation of Intercellular Calcium Signaling Through Calcium Interactions with Connexin-Based ChannelsOrellana J, Sánchez H, Schalper K, Figueroa V, Sáez J. Regulation of Intercellular Calcium Signaling Through Calcium Interactions with Connexin-Based Channels. 2012, 740: 777-794. PMID: 22453969, DOI: 10.1007/978-94-007-2888-2_34.
• p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival LesionsZoroquiain P, Fernandes BF, González S, Novais GN, Schalper KA, Burnier MN. p16ink4a Expression in Benign and Malignant Melanocytic Conjunctival Lesions. International Journal Of Surgical Pathology 2012, 20: 240-245. PMID: 22287653, DOI: 10.1177/1066896911435697.
• Modulation of gap junction channels and hemichannels by growth factorsSchalper K, Riquelme M, Brañes M, Martínez A, Vega J, Berthoud V, Bennett M, Sáez J. Modulation of gap junction channels and hemichannels by growth factors. Molecular Omics 2012, 8: 685-698. PMID: 22218428, DOI: 10.1039/c1mb05294b.
• Cation permeation through connexin 43 hemichannels is cooperative, competitive and saturable with parameters depending on the permeant speciesOrellana J, Díaz E, Schalper K, Vargas A, Bennett M, Sáez J. Cation permeation through connexin 43 hemichannels is cooperative, competitive and saturable with parameters depending on the permeant species. Biochemical And Biophysical Research Communications 2011, 409: 603-609. PMID: 21600880, PMCID: PMC3118918, DOI: 10.1016/j.bbrc.2011.05.031.
• Primary cerebral lymphomatoid granulomatosis in a HIV-positive patient. Case report.Schalper K, Valbuena J. Primary cerebral lymphomatoid granulomatosis in a HIV-positive patient. Case report. Revista Medica De Chile 2011, 139: 218-23. PMID: 21773660, DOI: /s0034-98872011000200012.
• Granulomatosis linfomatoide cerebral primaria en paciente VIH positivo: Caso clnicoSCHALPER K, VALBUENA J. Granulomatosis linfomatoide cerebral primaria en paciente VIH positivo: Caso clnico. Revista Medica De Chile 2011, 139: 218-223. DOI: 10.4067/s0034-98872011000200012.
• Connexin 43 hemichannels mediate the Ca2+ influx induced by extracellular alkalinizationSchalper KA, Sánchez HA, Lee SC, Altenberg GA, Nathanson MH, Sáez JC. Connexin 43 hemichannels mediate the Ca2+ influx induced by extracellular alkalinization. American Journal Of Physiology - Cell Physiology 2010, 299: c1504-c1515. PMID: 20881238, PMCID: PMC3774097, DOI: 10.1152/ajpcell.00015.2010.
• Cell membrane permeabilization via connexin hemichannels in living and dying cellsSáez J, Schalper K, Retamal M, Orellana J, Shoji K, Bennett M. Cell membrane permeabilization via connexin hemichannels in living and dying cells. Experimental Cell Research 2010, 316: 2377-2389. PMID: 20595004, DOI: 10.1016/j.yexcr.2010.05.026.
• Dysfunctions of the diffusional membrane pathways mediated by hemichannels in inherited and acquired human diseases.Schalper K, Orellana J, Berthoud V, Sáez J. Dysfunctions of the diffusional membrane pathways mediated by hemichannels in inherited and acquired human diseases. Current Vascular Pharmacology 2009, 7: 486-505. PMID: 19485891, DOI: 10.2174/157016109789043937.
• Modulation of Brain Hemichannels and Gap Junction Channels by Pro-Inflammatory Agents and Their Possible Role in NeurodegenerationOrellana JA, Sáez PJ, Shoji KF, Schalper KA, Palacios–Prado N, Velarde V, Giaume C, Bennett MV, Sáez JC. Modulation of Brain Hemichannels and Gap Junction Channels by Pro-Inflammatory Agents and Their Possible Role in Neurodegeneration. Antioxidants & Redox Signaling 2009, 11: 369-399. PMID: 18816186, PMCID: PMC2713807, DOI: 10.1089/ars.2008.2130.
• Connexin Hemichannel Composition Determines the FGF-1–induced Membrane Permeability and Free [Ca2+]i ResponsesSchalper K, Palacios-Prado N, Retamal M, Shoji K, Martínez A, Sáez J. Connexin Hemichannel Composition Determines the FGF-1–induced Membrane Permeability and Free [Ca2+]i Responses. Molecular Biology Of The Cell 2008, 19: 3501-3513. PMID: 18495870, PMCID: PMC2488314, DOI: 10.1091/mbc.e07-12-1240.
• Currently Used Methods for Identification and Characterization of HemichannelsSchalper K, Palacios-Prado N, Orellana J, Sáez J. Currently Used Methods for Identification and Characterization of Hemichannels. Cell Communication & Adhesion 2008, 15: 207-218. PMID: 18649191, DOI: 10.1080/15419060802014198.
• Possible Involvement of Different Connexin43 Domains in Plasma Membrane Permeabilization Induced by Ischemia-ReperfusionRetamal MA, Schalper KA, Shoji KF, Orellana JA, Bennett MV, Sáez JC. Possible Involvement of Different Connexin43 Domains in Plasma Membrane Permeabilization Induced by Ischemia-Reperfusion. The Journal Of Membrane Biology 2007, 218: 49-63. PMID: 17705051, DOI: 10.1007/s00232-007-9043-y.
• Opening of connexin 43 hemichannels is increased by lowering intracellular redox potentialRetamal MA, Schalper KA, Shoji KF, Bennett MV, Sáez JC. Opening of connexin 43 hemichannels is increased by lowering intracellular redox potential. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 8322-8327. PMID: 17494739, PMCID: PMC1895948, DOI: 10.1073/pnas.0702456104.